Bayer Healthcare Llc

Manufacturer Details

There are currently no manufacturer details available.

Bayer Healthcare Llc Drugs

Claritin

Claritin

adults and children 6 years and over

chew 2 tablets daily; not more than 2 tablets in 24 hours

children 2 to under 6 years of age
chew 1 tablet daily; not more than 1 tablet in 24 hours children under 2 years of age
ask a doctor
consumers with liver or kidney disease
ask a doctor
Good Neighbor Pharmacy ...

Good Neighbor Pharmacy Capsaicin

for skin protectant use apply as needed for diaper rash use: change wet and soiled diapers promptly cleanse the diaper area, and allow to dry apply ointment liberally as often as necessary, with each diaper change, especially at bedtime or anytime when exposure to wet diapers may be prolonged
Olay Regenerist Micro S...

Olay Regenerist Micro Sculpting Moisturizer Broad Spectrum Spf 30

Dosage and Administration

SPECTAM® Injectable is intended only for subcutaneous injection. The injection should be made under the loose skin on the top of the neck halfway between the head and the base of the neck. Thoroughly clean and sterilize syringes and needles before using (needles and syringes may be sterilized by boiling in water for 15 minutes).

Use all precautions to prevent contamination of contents of bottle. Injection site should be disinfected with a suitable disinfectant such as 70% isopropyl alcohol just prior to injecting SPECTAM®.

DOSAGE

Directions

Poults-
1. As an aid in the control of Chronic Respiratory Disease (CRD) associated with E. coli, inject newly-hatched turkey poults with 5 mg of spectinomycin subcutaneously. See dilution table below for 5 mg concentration in saline solution. 2. As an aid in the control of airsacculitis associated with Mycoplasma meleagridis sensitive to spectinomycin, inject newly-hatched turkey poults with 0.1 mL (10 mg) of spectinomycin subcutaneously.
Chicks-

As an aid in the control of mortality and to lessen severity of infections caused by M. synoviae, S. typhimurium, S. infantis and E coli, inject newly-hatched chicks subcutaneously with SPECTAM® Injectable diluted with sterile physiological saline solution to provide 2.5 to 5.0 mg of spectinomycin in a 0.2 mL dose. See dilution table below for 2.5 mg or 5.0 mg concentration in saline solution.

Dilution Table to administer SPECTAM® Injectable containing 100 mg/mL.

Caution: For large flock administration only utilizing appropriate equipment with aseptic techniques. Discard any diluted solution remaining.
Bayer 500 Mg

Bayer 500 Mg

There is currently no dosage information available for this product. We apologize for any inconvenience.
Tussin Cough And Chest ...

Tussin Cough And Chest Congestion Dm Adult

TREATMENT PERIOD – 6 consecutive days

Species

Concentration

Use Directions

CHICKENS

0.05%

Add 1 fl oz* to 2 gallons of drinking water or

25 fl oz to 50 gallons of drinking water

TURKEYS

0.025%

Add 1 fl oz* to 4 gallons of drinking water or

25 fl oz to 100 gallons of drinking water

Automatic Proportioners **Stock Solution-To make 2 gallons of Stock Solution use:

CHICKENS

Add 1gal Sulfadimethoxine 12.5% Drinking Water Solution to 1 gal of water

TURKEYS

Add 2 qts Sulfadimethoxine 12.5% Drinking Water Solution to 6 qts of water

* 1 fl oz Sulfadimethoxine 12.5% Oral Solution -30mL or 2 tablespoonfuls.

**Set proportioner to a feed rate of 1 fl oz of Sulfadimethoxine Stock Solution per gallon of water.

TREATMENT PERIOD – 5 consecutive days

DOSAGE:

SULFADIMETHOXINE IN WATER

DAIRY CALVESDAIRY HEIFERSAND BEEFCATTLE

25 mg/lb first day

WATER CONSUMPTION

followed by

(SUMMER)

(WINTER)

12.5 mg/lb/day

1 gallon/†

1 gallon/†

for 4 days.

100 lb. b.w.

150 lb. b.w.

FIRST DAY ADD:

1 pint (16 fl oz) to:

25 gallons

16 gallons

1 quart (32 fl oz) to:

50 gallons

33 gallons

1 gallon (128 fl oz) to:

200 gallons

127 gallons

NEXT 4 ADD:

1 pint (16 fl oz) to:

50 gallons

33 gallons

1 quart (32 fl oz) to:

100 gallons

66 gallons

1 gallon (128 fl oz) to:

400 gallons

266 gallons

† Dosage recommendations are based on an estimated summer water intake of 1 gal of water for every 100 lb of body weight per day, and an estimated winter water intake of 1 gal of water for every 150 lb of body weight per day.

For individual treatment of cattle, Sulfadimethoxine 12.5% Oral Solution may be given as a drench. Administer using initial dose of 25 mg/lb followed by 4 maintenance doses of 12.5 mg/lb/day. One fl oz will medicate one 150 lb animal initially and ½ fl oz will medicate one 150 lb animal on maintenance dose.

Bayer and the Bayer Cross are registered trademarks of Bayer. Manufactured for Bayer HealthCare LLC Shawnee Mission, KS 66201

81583455,R.O 200106.00

BARCODE

7-2408983455-3
Tussin Guifenesin Expec...

Tussin Guifenesin Expectrorant Syrup

There is currently no dosage information available for this product. We apologize for any inconvenience.
Amimax C

Amimax C

AmiMax™ C Injection (amikacin sulfate) should be administered subcutaneously or intramuscularly at a dosage of 10 mg/kg (5 mg/lb) twice daily. Dogs with skin and soft tissue infections should be treated for a minimum of 7 days and those with genitourinary infections should be treated for 7 to 21 days or until culture negative and asymptomatic. If no response is observed after three days of treatment, therapy should be discontinued and the case re-evaluated. Maximum duration of therapy should not exceed 30 days.
Preferred Plus Mucus Re...

Preferred Plus Mucus Relief

adults and children 6 to under 12 years of age (with adult supervision): 2 or 3 sprays in each nostril not more often than every 10 to 12 hours. Do not exceed 2 doses in any 24-hour period. children under 6 years of age: ask a doctor.
Shake well before use. Before using the first time, remove the protective cap from the tip and prime metered pump by depressing pump firmly several times. To spray, hold bottle with thumb at base and nozzle between first and second fingers. Without tilting head, insert nozzle into nostril. Fully depress rim with a firm, even stroke and sniff deeply. Wipe nozzle clean after use.
Midol Pm

Midol Pm

Directions

· do not take more than the recommended dose

· adults and children 12 years and older: take 2 caplets at bedtime if needed, or as directed by a doctor

· children under 12 years: do not use
Raminovet

Raminovet

Shake the vial thoroughly before opening.

RapinovetTM injection contains no antimicrobial preservatives. Strict aseptic techniques must always be maintained during handling since the vehicle is capable of supporting rapid growth of microorganisms. Failure to follow aseptic handling procedures may result in microbial contamination causing fever, infection/sepsis, and/or other life-threatening illness. Do not use if contamination is suspected.

Rapinovet™ injection should be prepared for use just prior to initiation of each individual anesthetic procedure. The vial rubber stopper should be disinfected using 70% isopropyl alcohol. The entire contents of the vial should be drawn into sterile syringes immediately after vials are opened. Administration should commence promptly and be completed within 6 hours after the vials are opened. Any unused product should be discarded within 6 hours.

Administer by intravenous injection only.

The emulsion should not be mixed with other therapeutic agents or injected into containers of infusion fluids prior to administration.

INDUCTION OF GENERAL ANETHESIA:

For induction, RapinovetTM injection should be titrated against the response of the patient over approximately 60 to 90 seconds or until clinical signs show the onset of anesthesia.

If RapinovetTM is injected too slowly (greater than 90 seconds), an inadequate plane of anesthesia can occur. If this occurs, an additional low dose (1.1 mg/kg) of propofol may be administered to facilitate intubation or the transition to inhalant maintenance anesthesia.

The average induction dose ranges and dosage rates for healthy dogs given propofol alone, or when propofol is preceded by a premedicant, are indicated in the following table (the Table is for guidance only; in practice, the dose should be based upon patient response):

Induction Dosage Guidelines for Dogs

Preanesthetic

Propofol Induction Dose

Propofol Rate of Administration

mg/kg

mg/lb

seconds

mg/kg/min

mL/kg/min

None

5.5-7.0

2.5-3.2

60-90

3.7-7.0

0.37-0.70

Acepromazine

4.0-4.4

1.8-2.0

60-90

2.7-4.4

0.27-0.44

Xylazine

2.2-3.3

1.0-1.5

60-90

1.5-3.3

0.15-0.33

Oxymorphone

2.2-3.3

1.0-1.5

60-90

1.5-3.3

0.15-0.33

Medetomidine

2.2-2.8

1.0-1.3

60-90

1.5-2.8

0.15-0.28

The required dosage of tranquilizers, sedatives, or analgesics administered as preanesthetic medications (listed below) may be lower than the label directions for their use as a single medication.1
Acepromazine 0.03-0.1 mg/kg IM,SC,IV Xylazine 0.25-0.5 mg/kg IV Xylazine 0.5-1.0 mg/kg IM,SC Oxymorphone 0.1-0.2 mg/kg IM,SC,IV Medetomidine 5.0-10.0 µg/kg IM
The use of the drugs listed above as preanesthetics for dogs markedly reduces propofol requirements. As with other sedative hypnotic agents, the amount of phenothiazine, opioid, and/or alpha2-agonist premedication will influence the response of the patient to an induction dose of RapinovetTM injection. The induction dose will also be influenced by the interval between the administration of premedication and induction, and by the rate of administration of propofol.

The average induction dose ranges and dosage rates for healthy cats given propofol alone, or when propofol is preceded by a premedicant, are indicated in the following table (the Table is for guidance only; in practice, the dose should be based on patient response).

Induction Dosage Guidelines for Cats

Preanesthetic

Propofol Induction Dose

Propofol Rate of Administration

mg/kg

mg/lb

seconds

mg/kg/min

mL/kg/min

None

8.0-13.2

3.6-6.0

60-90

5.3-13.2

0.53-1.32

Acepromazine

8.0-13.2

3.6-6.0

60-90

5.3-13.2

0.53-1.32

Butorphanol

8.0-13.2

3.6-6.0

60-90

5.3-13.2

0.53-1.32

Oxymorphone

8.0-13.2

3.6-6.0

60-90

5.3-13.2

0.53-1.32

Xylazine

7.0-12.0

3.2-5.5

60-90

4.7-12.0

0.47-1.20

The required dosage of tranquilizers, sedatives, or analgesics administered as preanesthetic medications (listed below) may be lower than the label directions for their use as a single medication.1,8,9
Acepromazine 0.03-0.1
mg/kg

IM,SC,IV
Butorphanol 0.1-0.4
mg/kg

IM, SC
Oxymorphone 0.1-0.4
mg/kg

IM,SC,IV
Xylazine 0.25-0.5
mg/kg

IV
Xylazine 0.5-1.0
mg/kg

IM,SC

The use of the drugs listed above as preanesthetics for cats may reduce propofol requirements. As with other sedative hypnotic agents, the amount of phenothiazine, opioid, and/or alpha2-agonist premedication will influence the response of the patient to an induction dose of RapinovetTM injection. The induction dose will also be influenced by the interval between the administration of premedication and induction, and by the rate of administration of propofol.

MAINTENANCE OF GENERAL ANESTHESIA:

A. Intermittent Propofol Injections: Anesthesia can be maintained by administering propofol in intermittent IV injections. Clinical response will be determined by the amount, the rate of administration, and the frequency of maintenance injections. The following Tables are provided for guidance:

Maintenance Dosage Guidelines for Dogs

Preanesthetic

Propofol Maintenance Dose

Propofol Rate of Administration

mg/kg

mg/lb

seconds

mg/kg/min

mL/kg/min

None

1.1-3.3

0.5-1.5

30-60

1.1-3.3

0.11-0.33

Acepromazine

1.1

0.5

30-60

1.1-2.2

0.11-0.22

Xylazine

1.1

0.5

30-60

1.1-2.2

0.11-0.22

Oxymorphone

1.1

0.5

30-60

1.1-2.2

0.11-0.22

Medetomidine

1.1

0.5

30-60

1.1-2.2

0.11-0.22

Repeated maintenance doses of propofol do not result in increased recovery times, indicating that the anesthetic effects of propofol are not cumulative in dogs.

Maintenance Dosage Guidelines for Cats

Preanesthetic

Propofol Maintenance Dose

Propofol Rate of Administration

mg/kg

mg/lb

seconds

mg/kg/min

mL/kg/min

None

1.1-4.4

05.-2.0

30-60

1.1-4.4

0.11-0.44

Acepromazine

1.1-4.4

05.-2.0

30-60

1.1-4.4

0.11-0.44

Butorphanol

1.1-4.4

05.-2.0

30-60

1.1-4.4

0.11-0.44

Oxymorphone

1.1-4.4

05.-2.0

30-60

1.1-4.4

0.11-0.44

Xylazine

1.1-2.2

0.5-1.0

30-60

1.1-2.2

0.11-0.22

Acepromazine/Butorphanol

1.1-3.3

0.5-1.5

30-60

1.1-3.3

0.11-0.33

Acepromazine/Oxymorphone

1.1-3.3

0.5-1.5

30-60

1.1-3.3

0.11-0.33

Repeated maintenance doses of propofol may result in slightly increased recovery times, indicating that the anesthetic effects of propofol may be cumulative in cats.

B. Maintenance by Inhalant Anesthetics: Clinical trials using propofol have shown that it may be necessary to use a higher initial concentration of the inhalant anesthetic than is usually required following induction using barbiturate anesthetics, due to rapid recovery from RapinovetTM injection.

OVERDOSAGE:

Rapid administration or accidental overdosage of RapinovetTM injection may cause neurologic and cardiopulmonary depression. Respiratory arrest (apnea) may be observed. In cases of respiratory depression, stop drug administration, establish a patent airway, and initiate assisted or controlled ventilation with oxygen. Cardiovascular depression should be treated with plasma expanders, pressor agents, antiarrhythmic agents, or other techniques as appropriate for the observed abnormality.

In feline safety studies using healthy cats and elevated doses of propofol, unexplained decreases in albumin, globulin, and total protein values were noted. Increases in bile acids and triglycerides were also noted and were probably due to the lipid content of the drug formulation. These transient changes were not clinically significant in healthy cats.
Midol Teen

Midol Teen

· do not take more than the recommended dose

· adults and children 12 years and older:

· take 2 caplets with water · repeat every 6 hours, as needed · do not exceed 6 caplets per day

· children under 12 years: consult a doctor
Bayer Chewable – ...

Bayer Chewable – Aspirin Regimen Low Dose Aspirin Cherry Flavored

• drink a full glass of water with each dose • adults and children 12 years and over: take 4 to 8 tablets every 4 hours not to exceed 48 tablets in 24 hours unless directed by a doctor • children under 12 years: consult a doctor

Directions

● drink a full glass of water with each dose

● adults and children 12 years and over: take 4 to 8 tablets every 4 hours not to

exceed 48 tablets in 24 hours unless directed by a doctor

● children under 12 years: consult a doctor
Equaline Childrens Acet...

Equaline Childrens Acetaminophen

Shake well before use. Spray directly onto the affected areas. If necessary, part hair coat so that ExpertCare™ Itch Relief Spray makes direct contact with the skin. May be used daily or as directed by your veterinarian. If redness or irritation persists or increases, discontinue use and contact your veterinarian.
Progesterone

Progesterone

wash affected area and dry thoroughly apply a thin layer over affected area twice daily (morning and night) supervise children in the use of this product use daily for 2 weeks if condition persists longer, ask a doctor this product is not effective on the scalp or nails
A And D First Aid

A And D First Aid

apply as needed
A And D Original

A And D Original

for skin protectant use apply as needed for diaper rash use: change wet and soiled diapers promptly cleanse the diaper area, and allow to dry apply ointment liberally as often as necessary, with each diaper change, especially at bedtime or anytime when exposure to wet diapers may be prolonged
Children Oscillococcinu...

Children Oscillococcinum

DOSAGE AND ADMINISTRATION: Prior to treatment, remove excessivehair and clean the lesion and adjacent area. Hold bottle upright 3 to 6inches from the lesion and depress the sprayer head twice. Administer 2to 4 times daily for 7 days.Each depression of the sprayer head delivers 0.7 mL of GentamicinSulfate With Betamethasone Valerate Topical Spray.
Dg Health All Day Aller...

Dg Health All Day Allergy

wash affected area and dry thoroughly apply a thin layer over affected area twice daily (morning and night) supervise children in the use of this product for athlete's foot: pay special attention to spaces between the toes; wear well-fitting, ventilated shoes and change shoes and socks at least once daily use daily for 4 weeks; if condition persists longer, ask a doctor to prevent athlete's foot, apply once or twice daily (morning and/or night) this product is not effective on the scalp or nails
Bayer Headache Relief

Bayer Headache Relief

drink a full glass of water with each dose adults and children 12 years and over: take 2 caplets every 6 hours not to exceed 8 caplets in 24 hours children under 12 years: consult a doctor
Colgate Sensitive Maxim...

Colgate Sensitive Maximum Strength Whitening

For treatment of uterine infections in mares, 2 grams (8 mL) of AmiMax™ E Solution (amikacin sulfate), mixed with 200 mL 0.9% Sodium Chloride Injection, USP and aseptically infused into the uterus daily for three consecutive days, has been found to be the most efficacious dosage.
Ovacyst

Ovacyst

There is currently no dosage information available for this product. We apologize for any inconvenience.
Prostamate

Prostamate

As with any multi-dose vial, practice aseptic techniques in withdrawing each dose. Adequately clean and disinfect the vial stopper prior to entry with a sterile needle and syringe. No vial closure should be entered more than 20 times.

Cattle: ProstaMate™ Sterile Solution is supplied at a concentration of 5 mg dinoprost per mL. ProstaMate™ is luteolytic in cattle at 25 mg (5 mL) administered intramuscularly.

Swine: ProstaMate™ Sterile Solution will induce parturition in swine at 10 mg (2 mL) when injected intramuscularly

Mares:
Evaluate the reproductive status of the mare. Administer a single intramuscular injection of 1 mg per 100 lbs (45.5 kg) body weight which is usually 1 mL to 2 mL ProstaMate™ Sterile Solution. Observe for signs of estrus by means of daily teasing with a stallion, and evaluate follicular changes on the ovary by palpation of the ovary per rectum. Some clinically anestrous mares will not express estrus but will develop a follicle which will ovulate. These mares may become pregnant if inseminated at the appropriate time relative to rupture of the follicle. Breed mares in estrus in a manner consistent with normal manage
Lotrimin

Lotrimin

wash affected area and dry thoroughly apply a thin layer over affected area twice daily (morning and night) supervise children in the use of this product for athlete's foot: pay special attention to spaces between the toes, wear well-fitting, ventilated shoes and change shoes and socks at least once daily for athlete's foot and ringworm, use daily for 4 weeks; for jock itch, use daily for 2 weeks if condition persists longer, ask a doctor this product is not effective on the scalp or nails
Afrin No Drip Extra Moi...

Afrin No Drip Extra Moisturizing

adults and children 6 to under 12 years of age (with adult supervision): 2 or 3 sprays in each nostril not more often than every 10 to 12 hours. Do not exceed 2 doses in any 24-hour period. children under 6 years of age: ask a doctor.
Shake well before use. Before using the first time, remove the protective cap from the tip and prime metered pump by depressing pump firmly several times. To spray, hold bottle with thumb at base and nozzle between first and second fingers. Without tilting head, insert nozzle into nostril. Fully depress rim with a firm, even stroke and sniff deeply. Wipe nozzle clean after use.
Walgreens Sterile Origi...

Walgreens Sterile Original Eye Drops

Marquis (15% w/w ponazuril) is to be used at a dose of 5 mg/kg (2.27 mg/lb) body weight once daily for a period of 28 days.

ADMINISTRATION:

Paste syringe assembly:

Before administration, the syringe barrel and plunger require assembly. Ensure plunger is clean and dry.

Step 1. End cap must be on syringe barrel when inserting plunger.

Step 2. Carefully insert reusable plunger into base of syringe barrel until it snaps into place, then remove end cap and gently apply pressure to the plunger until paste is seen at the tip of the syringe barrel.

Step 3. Return end cap to tip of paste syringe.

Administering Marquis (ponazuril) to the horse:

NOTE: The paste syringe is a multi-dose package. Ensure that the correct dose is administered with each use.

Step 1. Remove end cap and gently apply pressure to the plunger until paste is seen at the tip of the syringe barrel. Return end cap to tip of paste syringe.

Step 2. Determine weight of horse and insure the horse’s mouth contains no feed.

Step 3. To measure dose, dosage ring collar and barrel collar should be flush. Hold plunger and rotate dosage ring with the other hand to the weight of the horse.

Step 4. Remove end cap from tip of syringe barrel.

Step 5. The selected dose of paste should be deposited onto the back and top of the horse’s tongue. Introduce tip of paste syringe into the side of the horse’s mouth at the space between the front (incisor) and back (molar) teeth. Deposit paste on the horse’s tongue by depressing the plunger of the syringe as far as the dose ring permits. Remove tip of syringe from horse’s mouth.

Step 6. To aid swallowing of paste, immediately raise horse’s head for a few seconds after dosing.

Step 7. Clean the tip of the syringe with a clean disposable towel and return end cap to tip of syringe barrel.

Step 8. For the next daily dose, repeat steps 1-7.

NOTE: At the end of the prescribed treatment period, partially used syringes should be discarded.
Oxytocin

Oxytocin

(INTRAVENOUS, INTRAMUSCULAR OR SUBCUTANEOUS

For obstetrical use: U.S.P Units

Horses and Cows.........................100 (5 mL)

Sows and Ewes.........................30-50 (1½ to 2½ mL)

For milk letdown: U.S.P. Units

Cows............................................10-20 (½ to 1 mL)

Sows..............................................5-20 (¼ to 1 mL)
Gentamicin Sulfate

Gentamicin Sulfate

Chickens:

Each day-old chicken should be aseptically injected subcutaneously in the neck with GentaPoult® (Gentamicin Sulfate Injection) diluted with sterile, physiologic saline solution to provide 0.2 mg gentamicin in a 0.2 mL dose. This concentration can be provided by diluting GentaPoult® (Gentamicin Sulfate Injection) as follows:

GentaPoult®
(Gentamicin Sulfate Injection)

Sterile Saline

No. of

Dose/
Chicken mL mL Doses mL 1 99 500 0.2 2 198 1000 0.2 4 396 2000 0.2 10 990 5000 0.2 100 (1 vial) 9900 50000 0.2
Turkeys:

Each 1 to 3 day-old turkey should be aseptically injected subcutaneously in the neck with GentaPoult® (Gentamicin Sulfate Injection) diluted with sterile, physiologic saline solution to provide 1.0 mg gentamicin in a 0.2 mL dose. The dose should be injected under the loose skin on the top of the neck, halfway between the head and base of the neck. This concentration can be provided by diluting GentaPoult® (Gentamicin Sulfate Injection) as follows:

GentaPoult®
(Gentamicin Sulfate Injection)

Sterile Saline

No. of

Dose/
Turkey mL mL Doses mL 1 19 100 0.2 2 38 200 0.2 4 76 400 0.2 10 190 1000 0.2 100 (1 vial) 1900 10000 0.2
Clean and sterilize needles and syringes by boiling in water for 15 minutes prior to use. Disinfect the injection site and top of the bottle with a suitable disinfectant, such as 70% isopropyl alcohol. Use all precautions to prevent contamination of vial contents.
Relief Shampoo

Relief Shampoo

Shake well before use. Wet coat thoroughly. Apply sufficient Relief® Shampoo to lather well into hair coat. Contact with the skin is important. When entire coat is treated, allow lather to remain for 5 to 10 minutes. Rinse thoroughly with water. May be used as often as necessary or as directed by your veterinarian
Relief Creme Rinse

Relief Creme Rinse

Shake well before use. After routine or medicated shampooing, apply Relief ® Creme Rinse evenly and thoroughly into hair coat. Rub in well. May be used as a leave-on conditioner or lightly rinse the hair coat after 5 to 10 minutes of contact time. May be used as often as necessary or as directed by your veterinarian.
Relief Spray

Relief Spray

Shake well before use. Spray directly onto the affected areas. If necessary, part hair coat so that Relief® Spray makes direct contact with the skin. Rub in well. May be used dally or as directed by your veterinarian..
Chlorhexiderm 4%

Chlorhexiderm 4%

Wet coat thoroughly with water. Apply and lather ChlorhexiDerm® 4% Shampoo over the entire body, allowing for 5 to 10 minutes of contact time. Rinse completely with water. Repeat if necessary or as directed by your veterinarian.
Claritin

Claritin

Use only with enclosed dosing cup
adults and children 6 years and over: 2 teaspoonfuls (TSP) daily; do not take more than 2 teaspoonfuls (TSP) in 24 hours children 2 to under 6 years of age: 1 teaspoonful (TSP) daily; do not take more than 1 teaspoonful (TSP) in 24 hours children under 2 years of age: ask a doctor consumers with liver or kidney disease: ask a doctor
Expertcare Skin Care

Expertcare Skin Care

Shake well before use. Spray directly onto the affected areas. If necessary, part hair coat so that ExpertCare™ Itch Relief Spray makes direct contact with the skin. Rub in well May be used daily or as directed by your veterinarian. If redness or irritation persists or increases, discontinue use and contact your veterinarian.
T8 Keto Flush

T8 Keto Flush

Shake well before use. Apply T8 Keto® Flush liberally to affected area(s). Use cotton or absorbent material to clean excess solution and debris. Apply twice daily or as directed by your veterinarian.
Sulfadimethoxine Oral

Sulfadimethoxine Oral

Dogs: Infected Wounds, Abscesses and Dental Infections

Oral: 2.5-15.0 mg/lb body weight every 12 hours.

Duration: Treatment with clindamycin hydrochloride products may be continued up to a maximum of 28 days if clinical judgment indicates. Treatment of acute infections should not be continued for more that three or four days if no response to therapy is seen.

Dosage Schedule:

Clindamycin Hydrochloride Oral Liquid

Administer 1-6 mL/10 lb body weight every 12 hours.

Dogs: Osteomyelitis

Oral: 5.0-15.0 mg/lb body weight every 12 hours.

Duration: Treatment with Clindamycin Hydrochloride Oral Liquid is recommended for a minimum of 28 days. Treatment should not be continued for longer the 28 days if no response to therapy is seen.

Dosage Schedule:

Clindamycin Hydrochloride Oral Liquid

Administer 2-6 mL/10 lb body weight every 12 hours.

Cats: Infected Wounds, Abscesses and Dental Infections

Oral: 5.0-15.0 mg/lb body weight every 24 hours depending on the severity of the condition.

Duration: Treatment with Clindamycin Hydrochloride Oral Liquid may be continued up to a maximum for a minimum of 14 days if clinical judgment indicates. Treatment of acute infections should not be continued for more than three to four days if no clinical response to therapy is seen.

Dosage Schedule:

Clindamycin Hydrochloride Oral Liquid, to provide 5.0 mg/lb administer 1 mL/5 lb body weight once every 24 hours; to provide 15.0 mg/lb administer 3 mL/5 lb body weight once every 24 hours.
Laxative Pills Maximum ...

Laxative Pills Maximum Strength

adults and children 12 years and over: chew and swallow 1-2 chewable tablets every 2 to 4 hours as symptoms occur, or as directed by a doctor children under 12 years: consult a doctor do not take more than 10 chewable tablets in a 24-hour period
Zmax

Zmax

For intravenous use after reconstitution only.

2.1 Dose
• Dosage and duration of treatment depend on the severity of the factor VIII deficiency, the location and extent of bleeding, and the patient’s clinical condition. 1 Careful control of replacement therapy is especially important in cases of major surgery or life-threatening bleeding episodes. • Each vial of Kogenate FS has the recombinant factor VIII (rFVIII) potency in international units (IU, unit) stated on the label. One IU (unit), as defined by the World Health Organization standard for blood coagulation factor VIII, human, is approximately equal to the level of factor VIII activity found in 1 mL of fresh pooled human plasma. • The expected in vivo peak increase in factor VIII level expressed as IU/dL (or % normal) can be estimated using the following formulas:
Dosage (units) = body weight (kg) x desired factor VIII rise (IU/dL or % of normal) x 0.5 (IU/kg per IU/dL)
or IU/dL (or % normal) = Total Dose (IU)/body weight (kg) x 2 [IU/dL]/[IU/kg] • Titrate dose to the patient’s clinical response. Patients may vary in their pharmacokinetic (e.g., half-life, in vivo recovery) and clinical responses to Kogenate FS. 2,3,4 Although the dose can be estimated by the calculations above, it is highly recommended that appropriate laboratory tests, including serial factor VIII activity assays, are performed [see Warnings and Precautions (5.3) and Clinical Pharmacology (12.3)].
Control and Prevention of Bleeding Episodes

A guide for dosing Kogenate FS for the control and prevention of bleeding episodes is provided in Table 1. The goal of treatment is to maintain a plasma factor VIII activity level at or above the plasma levels (in % of normal or in IU/dL) outlined in Table 1.
Table 1 Dosing for Control and Prevention of Bleeding Episodes
Type of Bleeding Episodes

Factor VIII Level Required (IU/dL or % of normal)

Dose

(IU/kg)

Frequency of Doses

(hours)

Duration of Therapy

(days)

Minor

Early hemarthrosis, minor muscle or oral bleeds.

20 – 40

10 – 20

Repeat dose if there is evidence of further bleeding.

Until bleeding is resolved

Moderate

Bleeding into muscles, bleeding into the oral cavity, definite hemarthroses, and known trauma.

30 – 60

15 – 30

12 – 24

Until bleeding is resolved

Major

Gastrointestinal bleeding. Intracranial, intra-abdominal or intrathoracic bleeding, central nervous system bleeding, bleeding in the retropharyngeal or retroperitoneal spaces, or iliopsoas sheath.

Fractures.

Head trauma.

80 – 100

Initial: 40 – 50

Repeat: 20 – 25

8 – 12

Until bleeding is resolved

Peri-operative Management

A guide for dosing Kogenate FS during surgery (perioperative management) is provided in Table 2. The goal of treatment is to maintain a plasma factor VIII activity level at or above the plasma level (in % of normal or in IU/dL) outlined in Table 2.
Table 2 Dosing for Peri-operative Management
Type of Surgery

Factor VIII Level Required (IU/dL or % of normal)

Dose

(IU/kg)

Frequency of Doses

(hours)

Duration of Therapy

(days)

Minor

Including tooth extraction

30 – 60

15 – 30

12 – 24

Until bleeding is resolved.

Major

Examples include tonsillectomy, inguinal herniotomy, synovectomy, total knee replacement, craniotomy, osteosynthesis, trauma.

100

50

Pre-operatively to achieve 100% activity.

6 – 12 to keep FVIII activity in desired range

Until healing is complete.

Routine Prophylaxis in Adults

The recommended dose for routine prophylaxis is 25 units per kg of body weight three times per week.

Routine Prophylaxis in Children

The recommended dose for routine prophylaxis is 25 units per kg of body weight every other day.5

2.2 Preparation and Reconstitution

Kogenate FS is administered by intravenous injection after reconstitution. Patients should follow the specific reconstitution and administration procedures provided by their physicians.

Reconstitute and administer Kogenate FS with the components provided with each package. If any component of the package is opened or damaged, do not use this component.

Product reconstitution, administration, and handling of the administration set and needles must be done with caution because percutaneous puncture with a needle contaminated with blood can transmit infectious viruses, including HIV (AIDS) and hepatitis. Place needles in a sharps container after single use. Discard all equipment, including any reconstituted Kogenate FS product, in an appropriate container. Obtain immediate medical attention if injury occurs.

For any questions about the handling, reconstitution and administration of Kogenate FS, contact Bayer Medical Communications at 1-888-84-BAYER (1-888-842-2937).

For instructions, patients should follow the recommendations in the FDA-Approved Patient Labeling.

The procedures below are provided as general guidelines for the reconstitution of Kogenate FS with BIO-SET®, a needleless self-contained reconstitution system.
• Work on a clean surface and wash hands thoroughly using soap and warm water before performing the procedures. • Reconstitute the product with the components provided with each package. If any component of the package is opened or damaged, do not use this component. • Filter the reconstituted product to remove potential particulate matter in the solution. Filtering can be achieved by following the administration steps as described below.
Vacuum Transfer and Reconstitution
1. Prepare the product under aseptic conditions. 2. Warm the unopened diluent (as needed) and the concentrate to a temperature not to exceed 37°C or 99°F. 3. Remove the cap from the concentrate. Take out the prefilled diluent syringe and remove the tip cap. (Fig. A). 4. Connect the prefilled diluent syringe to the concentrate vial by gently screwing on to the BIO-SET connection (Fig. B). 5. Place the vial on a rigid, non-skid surface and hold it firmly with one hand. With the other hand, strongly press down the fingerplate near the syringe tip using your thumb and index finger (Fig. C) until the fingerplate meets the top edge of the BIO-SET. This confirms that the system is activated (Fig. D). 6. Grasp the plunger rod by the top plate and remove from carton. Avoid touching the sides and threads of the plunger rod. Immediately screw plunger rod into the syringe rubber stopper (Fig. E). 7. Inject the diluent into the concentrate by pushing down the plunger rod slowly (Fig. F). 8. Swirl gently until completely dissolved without creating excessive foaming (Fig. G). 9. Invert vial/syringe and transfer the solution into syringe that was used to deliver the diluent (Fig. H). Ensure that the entire contents of the reconstituted Kogenate FS vial are drawn into the syringe. 10. Unscrew the filled syringe to disconnect it from the empty concentrate vial (Fig. I). 11. Attach the filled syringe to the administration set provided and immediately inject intravenously (Fig. J). 12. If the same patient is to receive more than one vial, the diluent syringe provided should be used to reconstitute the powder in the product vials as described above. The reconstituted solutions should then be combined in a larger plastic syringe (not provided) (Fig. J).
2.3 Administration

For intravenous use after reconstitution only.
• Inspect Kogenate FS visually for particulate matter and discoloration prior to administration, wherever solution and container permit. Do not use Kogenate FS if you notice any particulates or turbidity in the solution. • Store the reconstituted Kogenate FS at room temperature prior to administration, but administer it within 3 hours. • Administer Kogenate FS with the administration set provided with the product as it incorporates an in-line filter. In situations where the administration set provided cannot be used (e.g. when infusing into a peripheral or central line), use a separate filter compatible with Kogenate FS. NOTE: Do not use the administration set provided with the product to draw blood because it contains an in-line filter. When blood must be withdrawn prior to an infusion, use an administration set without a filter, then infuse Kogenate FS through an injection filter. For any questions about compatible separate filters, contact Bayer Medical Communications at 1-888-84-BAYER (1-888-842-2937). • Administer Kogenate FS over a period of 1 to 15 minutes. Adapt the rate of administration to the response of each individual patient. Determine the pulse rate before and during administration of Kogenate FS. If there is a significant increase in pulse rate, reduce the rate of administration or temporarily halt the infusion allowing the symptoms to disappear promptly.
Furosemide

Furosemide

The usual dosage of Furosemide Injection 5% is 1 to 2 mg/lb. body weight (approximately 2.5 to 5 mg/kg). The lower dosage is suggested for cats. Administer once or twice daily at 6 to 8 hour intervals either intravenously or intramuscularly. A prompt diuresis usually ensues from the initial treatment. Diuresis may be initiated by the parenteral administration of Furosemide Injection 5%.

The dosage should be adjusted to the individual’s response. In severe edematous or refractory cases, the dose may be doubled or increased by increments of 1 mg per pound body weight. The established effective dose should be administered once or twice daily. The daily schedule of administration can be timed to control the period of micturition for the convenience of the client or veterinarian. Mobilization of the edema may be most efficiently and safely accomplished by utilizing an intermittent daily dosage schedule, i.e., every other day or 2 to 4 consecutive days weekly.

Diuretic therapy should be discontinued after reduction of the edema, or maintained after determining a carefully programmed dosage schedule to prevent recurrence of edema. For long-term treatment, the dose can generally be lowered after the edema has once been reduced. Re-examination and consultations with client will enhance the establishment of a satisfactorily programmed dosage schedule. Clinical examination and serum BUN, CO2 and electrolyte determinations should be performed during the early period of therapy and periodically thereafter, especially in refractory cases. Abnormalities should be corrected or the drug temporarily withdrawn.

DOSAGE: PARENTERAL:

DOGS & CATS

Administer intramuscularly or intravenously 1/4 to 1/2 mL per 10 pounds body weight. Administer once or twice daily, permitting a 6 to 8 hour interval between treatments. In refractory or severe edematous cases the dosage may be doubled or increased by increments of 1 mg per pound body weight as recommended in preceding paragraphs. “Dosage and Administration”.

HORSE

The individual dose is 250 mg to 500 mg (5 to 10 mL) administered intramuscularly or intravenously once or twice daily at 6 to 8 hour intervals until desired results are achieved. The veterinarian should evaluate the degree of edema present and adjust dosage schedule accordingly. Do not use in horses intended for human consumption.

CATTLE

The individual dose administered intramuscularly or intravenously is 500 mg (10 mL) once daily or 250 mg (5 mL) twice daily at 12 hour intervals. Treatment not to exceed 48 hours postparturition.

Milk taken from animals during treatment and for 48 hours (four milkings) after the last treatment must not be used for food. Cattle must not be slaughtered for food within 48 hours following last treatment.
Kogenate Fs

Kogenate Fs

For intravenous use after reconstitution only.

2.1 Dose
• Dosage and duration of treatment depend on the severity of the factor VIII deficiency, the location and extent of bleeding, and the patient’s clinical condition. 1 Careful control of replacement therapy is especially important in cases of major surgery or life-threatening bleeding episodes. • Each vial of Kogenate FS has the recombinant factor VIII (rFVIII) potency in international units (IU, unit) stated on the label. One IU (unit), as defined by the World Health Organization standard for blood coagulation factor VIII, human, is approximately equal to the level of factor VIII activity found in 1 mL of fresh pooled human plasma. • The expected in vivo peak increase in factor VIII level expressed as IU/dL (or % normal) can be estimated using the following formulas: Dosage (units) = body weight (kg) x desired factor VIII rise (IU/dL or % of normal) x 0.5 (IU/kg per IU/dL) or IU/dL (or % normal) = Total Dose (IU)/body weight (kg) x 2 [IU/dL]/[IU/kg] • Titrate dose to the patient’s clinical response. Patients may vary in their pharmacokinetic (e.g., half-life, in vivo recovery) and clinical responses to Kogenate FS. 2,3,4 Although the dose can be estimated by the calculations above, it is highly recommended that appropriate laboratory tests, including serial factor VIII activity assays, are performed [see Warnings and Precautions (5.3) and Clinical Pharmacology (12.3)].
Control and Prevention of Bleeding Episodes

A guide for dosing Kogenate FS for the control and prevention of bleeding episodes is provided in Table 1. The goal of treatment is to maintain a plasma factor VIII activity level at or above the plasma levels (in % of normal or in IU/dL) outlined in Table 1.
Table 1 Dosing for Control and Prevention of Bleeding Episodes
Type of Bleeding Episodes

Factor VIII Level Required (IU/dL or % of normal)

Dose

(IU/kg)

Frequency of Doses

(hours)

Duration of Therapy

(days)

Minor

Early hemarthrosis, minor muscle or oral bleeds.

20 – 40

10 – 20

Repeat dose if there is evidence of further bleeding.

Until bleeding is resolved

Moderate

Bleeding into muscles, bleeding into the oral cavity, definite hemarthroses, and known trauma.

30 – 60

15 – 30

12 – 24

Until bleeding is resolved

Major

Gastrointestinal bleeding. Intracranial, intra-abdominal or intrathoracic bleeding, central nervous system bleeding, bleeding in the retropharyngeal or retroperitoneal spaces, or iliopsoas sheath.

Fractures.

Head trauma.

80 – 100

Initial: 40 – 50

Repeat: 20 – 25

8 – 12

Until bleeding is resolved

Peri-operative Management

A guide for dosing Kogenate FS during surgery (perioperative management) is provided in Table 2. The goal of treatment is to maintain a plasma factor VIII activity level at or above the plasma level (in % of normal or in IU/dL) outlined in Table 2.
Table 2 Dosing for Peri-operative Management
Type of Surgery

Factor VIII Level Required (IU/dL or % of normal)

Dose

(IU/kg)

Frequency of Doses

(hours)

Duration of Therapy

(days)

Minor

Including tooth extraction

30 – 60

15 – 30

12 – 24

Until bleeding is resolved.

Major

Examples include tonsillectomy, inguinal herniotomy, synovectomy, total knee replacement, craniotomy, osteosynthesis, trauma.

100

50

Pre-operatively to achieve 100% activity.

6 – 12 to keep FVIII activity in desired range

Until healing is complete.

Routine Prophylaxis in Adults

The recommended dose for routine prophylaxis is 25 units per kg of body weight three times per week.

Routine Prophylaxis in Children

The recommended dose for routine prophylaxis is 25 units per kg of body weight every other day.5

2.2 Preparation and Reconstitution

Kogenate FS is administered by intravenous injection after reconstitution. Patients should follow the specific reconstitution and administration procedures provided by their physicians.

Reconstitute and administer Kogenate FS with the components provided with each package. If any component of the package is opened or damaged, do not use this component.

Product reconstitution, administration, and handling of the administration set and needles must be done with caution because percutaneous puncture with a needle contaminated with blood can transmit infectious viruses, including HIV (AIDS) and hepatitis. Place needles in a sharps container after single use. Discard all equipment, including any reconstituted Kogenate FS product, in an appropriate container. Obtain immediate medical attention if injury occurs.

For any questions about the handling, reconstitution and administration of Kogenate FS, contact Bayer Medical Communications at 1-888-84-BAYER (1-888-842-2937).

For instructions, patients should follow the recommendations in the FDA-Approved Patient Labeling.

The procedures below are provided as general guidelines for the reconstitution of Kogenate FS.
• Work on a clean surface and wash hands thoroughly using soap and warm water before performing the procedures. • Reconstitute the product with the components provided with each package. If any component of the package is opened or damaged, do not use this component. • Filter the reconstituted product to remove potential particulate matter in the solution. Filtering can be achieved by following the reconstitution steps as described below.
Vacuum Transfer and Reconstitution
1. Prepare the product under aseptic conditions. 2. Warm the unopened diluent and the concentrate to a temperature not to exceed 37°C or 99°F. 3. After removing the plastic flip-top caps (Fig. A), aseptically cleanse the rubber stoppers of both vials with alcohol, being careful not to handle the rubber stopper. 4. Remove the protective cover from one end of the plastic transfer needle cartridge and penetrate the stopper of the diluent vial (Fig. B). 5. Remove the remaining portion of the protective cover, invert the diluent vial and penetrate the rubber seal on the concentrate vial (Fig. C) with the needle at an angle. 6. The vacuum will draw the diluent into the concentrate vial. Hold the diluent vial at an angle to the concentrate vial in order to direct the jet of diluent against the wall of the concentrate vial (Fig. C). Avoid excessive foaming. If the diluent does not get drawn into the vial, there is insufficient vacuum and the product should not be used. 7. After removing the diluent vial and transfer needle (Fig. D), swirl until completely dissolved without creating excessive foaming (Fig. E). 8. Re-swab top of reconstituted Kogenate FS vial with alcohol. Allow the stopper to air dry. 9. After the concentrate powder is completely dissolved, withdraw the solution into the syringe through the filter needle that is supplied in the package (Fig. F). Replace the filter needle with the administration set provided and inject intravenously. 10. If the same patient is to receive more than one vial, the contents of two vials may be drawn into the same syringe through a separate unused filter needle before attaching the vein needle.
2.3 Administration

For intravenous use after reconstitution only.
• Inspect Kogenate FS visually for particulate matter and discoloration prior to administration, wherever solution and container permit. Do not use Kogenate FS if you notice any particulates or turbidity in the solution. • Store the reconstituted Kogenate FS at room temperature prior to administration, but administer it within 3 hours. • Administer Kogenate FS with the administration set provided with the product as it incorporates an in-line filter. In situations where the administration set provided cannot be used (e.g. when infusing into a peripheral or central line), use a separate filter compatible with Kogenate FS. NOTE: Do not use the administration set provided with the product to draw blood because it contains an in-line filter. When blood must be withdrawn prior to an infusion, use an administration set without a filter, then infuse Kogenate FS through an injection filter. For any questions about compatible separate filters, contact Bayer Medical Communications at 1-888-84-BAYER (1-888-842-2937). • Administer Kogenate FS over a period of 1 to 15 minutes. Adapt the rate of administration to the response of each individual patient. Determine the pulse rate before and during administration of Kogenate FS. If there is a significant increase in pulse rate, reduce the rate of administration or temporarily halt the infusion allowing the symptoms to disappear promptly.
Relief Hc Shampoo

Relief Hc Shampoo

Shake well before use. Wet coat thoroughly. Apply sufficient Relief HC Shampoo to lather well into hair coat. Contact with the skin is important. When entire coat is treated, allow lather to remain for 5 to 10 minutes. Rinse thoroughly with water. May be used as often as necessary or as directed by your veterinarian.
Kogenate Fs

Kogenate Fs

For intravenous use after reconstitution only.

2.1 Dose
• Dosage and duration of treatment depend on the severity of the factor VIII deficiency, the location and extent of bleeding, and the patient’s clinical condition. 1 Careful control of replacement therapy is especially important in cases of major surgery or life-threatening bleeding episodes. • Each vial of Kogenate FS has the recombinant factor VIII (rFVIII) potency in international units (IU, unit) stated on the label. One IU (unit), as defined by the World Health Organization standard for blood coagulation factor VIII, human, is approximately equal to the level of factor VIII activity found in 1 mL of fresh pooled human plasma. • The expected in vivo peak increase in factor VIII level expressed as IU/dL (or % normal) can be estimated using the following formulas:
Dosage (units) = body weight (kg) x desired factor VIII rise (IU/dL or % of normal) x 0.5 (IU/kg per IU/dL)

or

IU/dL (or % normal) = Total Dose (IU)/body weight (kg) x 2 [IU/dL]/[IU/kg]
• Titrate dose to the patient’s clinical response. Patients may vary in their pharmacokinetic (e.g., half-life, in vivo recovery) and clinical responses to Kogenate FS. 2,3,4 Although the dose can be estimated by the calculations above, it is highly recommended that appropriate laboratory tests, including serial factor VIII activity assays, are performed [see Warnings and Precautions (5.3) and Clinical Pharmacology (12.3)].
Control and Prevention of Bleeding Episodes

A guide for dosing Kogenate FS for the control and prevention of bleeding episodes is provided in Table 1. The goal of treatment is to maintain a plasma factor VIII activity level at or above the plasma levels (in % of normal or in IU/dL) outlined in Table 1.
Table 1 Dosing for Control and Prevention of Bleeding Episodes
Type of Bleeding Episodes

Factor VIII Level Required (IU/dL or % of normal)

Dose

(IU/kg)

Frequency of Doses

(hours)

Duration of Therapy

(days)

Minor

Early hemarthrosis, minor muscle or oral bleeds.

20 – 40

10 – 20

Repeat dose if there is evidence of further bleeding.

Until bleeding is resolved

Moderate

Bleeding into muscles, bleeding into the oral cavity, definite hemarthroses, and known trauma.

30 – 60

15 – 30

12 – 24

Until bleeding is resolved

Major

Gastrointestinal bleeding. Intracranial, intra-abdominal or intrathoracic bleeding, central nervous system bleeding, bleeding in the retropharyngeal or retroperitoneal spaces, or iliopsoas sheath.

Fractures.

Head trauma.

80 – 100

Initial: 40 – 50

Repeat: 20 – 25

8 – 12

Until bleeding is resolved

Peri-operative Management

A guide for dosing Kogenate FS during surgery (perioperative management) is provided in Table 2. The goal of treatment is to maintain a plasma factor VIII activity level at or above the plasma level (in % of normal or in IU/dL) outlined in Table 2.
Table 2 Dosing for Peri-operative Management
Type of Surgery

Factor VIII Level Required (IU/dL or % of normal)

Dose

(IU/kg)

Frequency of Doses

(hours)

Duration of Therapy

(days)

Minor

Including tooth extraction

30 – 60

15 – 30

12 – 24

Until bleeding is resolved.

Major

Examples include tonsillectomy, inguinal herniotomy, synovectomy, total knee replacement, craniotomy, osteosynthesis, trauma.

100

50

Pre-operatively to achieve 100% activity.

6 – 12 to keep FVIII activity in desired range

Until healing is complete.

Routine Prophylaxis in Adults

The recommended dose for routine prophylaxis is 25 units per kg of body weight three times per week.

Routine Prophylaxis in Children

The recommended dose for routine prophylaxis is 25 units per kg of body weight every other day.5

2.2 Preparation and Reconstitution

Kogenate FS is administered by intravenous injection after reconstitution. Patients should follow the specific reconstitution and administration procedures provided by their physicians.

Reconstitute and administer Kogenate FS with the components provided with each package. If any component of the package is opened or damaged, do not use this component.

Product reconstitution, administration, and handling of the administration set and needles must be done with caution because percutaneous puncture with a needle contaminated with blood can transmit infectious viruses, including HIV (AIDS) and hepatitis. Place needles in a sharps container after single use. Discard all equipment, including any reconstituted Kogenate FS product, in an appropriate container. Obtain immediate medical attention if injury occurs.

For any questions about the handling, reconstitution and administration of Kogenate FS, contact Bayer Medical Communications at 1-888-84-BAYER (1-888-842-2937).

For instructions, patients should follow the recommendations in the FDA-Approved Patient Labeling.

The procedures below are provided as general guidelines for the reconstitution of Kogenate FS provided with a sterile vial adapter with 15-micrometer filter and a prefilled diluent syringe, which together serve as an alternative needleless reconstitution system.
• Work on a clean surface and wash hands thoroughly using soap and warm water before performing the procedures. • Reconstitute Kogenate FS with the components provided with each package. If any component of the package is opened or damaged, do not use this component. • Filter the reconstituted product prior to administration to remove potential particulate matter in the solution. Filtering can be achieved by using the vial adapter.
Vacuum Transfer and Reconstitution
1. Prepare the product under aseptic conditions. 2. Warm both unopened vial and syringe in your hands to a comfortable temperature (do not exceed 37°C or 99°F). 3. Remove protective cap from the vial (A). Aseptically cleanse the rubber stopper with alcohol, being careful not to handle the rubber stopper. 4. Place product vial on a firm, non-skid surface. Peel off the paper cover on the vial adapter plastic housing. Do not remove the adapter from the plastic housing. Holding the adapter housing, place over the product vial and firmly press down (B). The adapter will snap over the vial cap. Do not remove the adapter housing at this step. 5. Holding the syringe by the barrel, snap the syringe cap off the tip (C). Do not touch the syringe tip with your hand or any surface. Set the syringe aside for further use. 6. Now remove and discard the adapter housing (D). 7. Attach the prefilled syringe to the threaded vial adapter by turning clockwise (E). 8. Grasp the plunger rod by the top plate and remove from carton. Avoid touching the sides and threads of the plunger rod. Immediately attach the plunger rod by turning it firmly clockwise into the threaded syringe rubber stopper (F). 9. Inject the diluent by slowly pushing down on the plunger rod (G). 10. Swirl vial gently until all material is dissolved (H). Do not shake vial. Be sure that the powder is completely dissolved. Do not use solutions containing visible particles or that are cloudy. 11. Withdraw solution into the syringe by holding the vial on end above the vial adapter and syringe (I) then draw the plunger rod out slowly and smoothly. Ensure that the entire content of the vial is drawn into the syringe. 12. With the plunger rod in place, remove the syringe from the vial adapter (the latter should remain attached to the vial). Attach the syringe to the administration set provided and inject intravenously (J). 13. If the same patient is to receive more than one bottle, reconstitute each bottle with the diluent syringe provided then combine solutions in a larger syringe (not provided) and administer as usual.
2.3 Administration

For intravenous use after reconstitution only.
• Inspect Kogenate FS visually for particulate matter and discoloration prior to administration, wherever solution and container permit. Do not use Kogenate FS if you notice any particulates or turbidity in the solution. • Store the reconstituted Kogenate FS at room temperature prior to administration, but administer it within 3 hours. • Administer Kogenate FS using the administration set provided over a period of 1 to 15 minutes. Adapt the rate of administration to the response of each individual patient. Determine the pulse rate before and during administration of Kogenate FS. If there is a significant increase in pulse rate, reduce the rate of administration or temporarily halt the infusion allowing the symptoms to disappear promptly.
Malaseb

Malaseb

DIRECTIONS: Wet coat thoroughly with water. Apply and lather Malaseb® Shampoo over the entire body, allowing 10 minutes of contact time. Rinse completely with water. Do not allow animal to lick while bathing to prevent ingestion. Repeat twice weekly until symptoms subside, then weekly, or as directed by your veterinarian.

Bayer Healthcare Llc

Manufacturer Details

Share This Page

Bayer Healthcare Llc Drugs